Corneal Endothelial Dystrophy - Pipeline Insight, 2024

This “Corneal endothelial dystrophy - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Corneal endothelial dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Corneal endothelial dystrophy Understanding

Corneal endothelial dystrophy: Overview

The term “corneal endothelial dystrophy” refers to a group of diseases that are characterized by a slowly progressive endogenous degeneration of corneal endothelium and are at least in part due to genetic predisposition. The corneal endothelial dystrophies are congenital hereditary endothelial dystrophy 1 (CHED1), congenital hereditary endothelial dystrophy 2 (CHED2), posterior polymorphous corneal dystrophy (PPCD) and Fuchs endothelial corneal dystrophy (FECD). In all cases, degeneration of corneal endothelium ultimately leads to severely impaired vision or blindness, but the molecular pathologies remain largely unknown. Recent efforts have shed more light on the molecular mechanisms of these diseases, and the latest genetic findings enforce the idea of a gradual continuum between endothelial dystrophies. Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane.

Corneal endothelial dystrophy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Corneal endothelial dystrophy pipeline landscape is provided which includes the disease overview and Corneal endothelial dystrophy treatment guidelines. The assessment part of the report embraces, in depth Corneal endothelial dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Corneal endothelial dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Corneal endothelial dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Corneal endothelial dystrophy.

Corneal endothelial dystrophy Emerging Drugs Chapters

This segment of the Corneal endothelial dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Corneal endothelial dystrophy Emerging Drugs

TTHX1114: Trefoil Therapeutics TTHX1114 is a proprietary, engineered form of the naturally occurring molecule Fibroblast Growth Factor-1 (FGF-1), which naturally functions to stimulate cell proliferation and migration as well as protect cells from stress and injury. TTHX1114 has been engineered to increase FGF-1’s pharmacodynamic half-life, enabling its use as a pharmaceutical. TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer. Currently, it is in Phase II stage of development to treat Corneal Endothelial Dystrophy.

Netarsudil mesylate: Aerie Pharmaceuticals Netarsudil mesylate ophthalmic solution has been developed by Aerie Pharmaceuticals, under a licence from Duke University Medical Center, for the reduction of intraocular pressure in open-angle glaucoma, ocular hypertension and for reducing or resolving corneal edema in Fuchs' endothelial dystrophy.

Corneal endothelial dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Corneal endothelial dystrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Corneal endothelial dystrophy

There are approx. 4+ key companies which are developing the therapies for Corneal endothelial dystrophy. The companies which have their Corneal endothelial dystrophy drug candidates in the most advanced stage, i.e. phase II include, Trefoil Therapeutics.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Corneal endothelial dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Corneal endothelial dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Corneal endothelial dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Corneal endothelial dystrophy drugs.

Corneal endothelial dystrophy Report Insights

• Corneal endothelial dystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Corneal endothelial dystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Corneal endothelial dystrophy drugs?
• How many Corneal endothelial dystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Corneal endothelial dystrophy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Corneal endothelial dystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Corneal endothelial dystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trefoil Therapeutics
• Aerie Pharmaceuticals
• Kowa Research Institute, Inc.
• Emmecell
• Surrozen

Key Products

• TTHX1114
• Netarsudil mesylate
• K-321
• EO2002